Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Pegfilgrastim Biosimilars Market Report 2024

Pegfilgrastim Biosimilars Global Market Report 2025 – By Application (Chemotherapy Treatment, Transplantation, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

Pegfilgrastim Biosimilars Global Market Report 2025

Report Price : $4490.00 | Pages : 250 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Pegfilgrastim Biosimilars Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Pegfilgrastim Biosimilars Market Definition

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

The different applications of pegfilgrastim biosimilars are chemotherapy treatment, Transplantation, and others. Chemotherapy is a cancer treatment that involves the administration of one or more anti-cancer medications as part of a defined protocol. The various distribution channels include hospital pharmacies, retail pharmacies, and mail-order pharmacies.

Pegfilgrastim Biosimilars Market Segmentation

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology

Pegfilgrastim Biosimilars Market Size and growth rate 2025 to 2029: Graph

Pegfilgrastim Biosimilars Market Size 2025 And Growth Rate

The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.56 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs.

Pegfilgrastim Biosimilars Market Growth Forecast

The pegfilgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $3.44 billion in 2029 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing prevalence of cancer, aging population, increasing number of approvals, and targets and incentives. Major trends in the forecast period include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in R&D activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on M&A growth strategies to expand the customer base and their geographic markets, and increasing focus towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.

Book your 30 minutes free consultation with our research experts

Contact Us

Pegfilgrastim Biosimilars Market Driver: Government Initiatives Drive Growth In Pegfilgrastim Biosimilars Market

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the pegfilgrastim biosimilars market.

Pegfilgrastim Biosimilars Market Driver: Increase Incidence Of Cancer Are Anticipated To Fuel The Growth Of The Pegfilgrastim Biosimilars Market

The increased incidence of cancer is expected to propel the pegfilgrastim biosimilars market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Pegfilgrastim biosimilars are used to reduce the risk of infection in cancer patients undergoing chemotherapy by stimulating white blood cell production.For instance, in February 2024, according to The World Health Organization (WHO), a Switzerland-based Intergovernmental organization, by 2050, over 35 million new cancer cases are expected, reflecting a 77% rise from the estimated 20 million cases in 2022. Therefore, the increased incidence of cancer is driving the pegfilgrastim biosimilars market.

Global Pegfilgrastim Biosimilars Market Major Players

Major companies operating in the pegfilgrastim biosimilars market include Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Reddy's Laboratories, Shanghai Henlius Biotech, Alvotech, EirGenix, Bharat Biotech, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Global Pegfilgrastim Biosimilars Market Trend: Strategic Collaborations Fueling New Launches In The Pegfilgrastim Biosimilar Market

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over the past few years. For instance, in May 2023, Amneal Pharmaceuticals, a US-based generics and specialty pharmaceutical company, partnered with Kashiv Biosciences, a US-based integrated biosciences company, to develop and introduce Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. FYLNETRA is a preservative-free, clear solution offered in a 6 mg/0.6 mL single-dose prefilled syringe. It’s used to reduce infection risks, specifically febrile neutropenia, in patients with non-myeloid cancers undergoing certain myelosuppressive anti-cancer treatments.

Global Pegfilgrastim Biosimilars Market Trend: High Quality Biosimilar For Providing Better Alternative

Major companies operating in the pegfilgrastim biosimilars market are launching high-quality pegfilgrastim biosimilars such as the Stimufend to provide better alternatives. Stimufend is a therapeutic drug designed to assist cancer patients in addressing neutropenia. For instance, in February 2023, Fresenius Kabi, a Germany-based healthcare company that specializes in pharmaceuticals, medical technologies, and nutrition products launched its first pegfilgrastim biosimilar, Stimufend in the U.S, which is available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with a built-in needle guard, Stimufend launch marks the inaugural entry of the company into the U.S. biosimilars market for cancer care. This product provides healthcare professionals with a high-quality treatment alternative.

Pegfilgrastim Biosimilars Market Merger And Acquisition: Biocon Biologics Expands Biosimilar Footprint With Acquisition Of Viatris' Biosimilar Business

In February 2022, Biocon Biologics Ltd., an India-based fully integrated biopharmaceutical company, acquired Viatris' biosimilar business for $3.34 billion. Through this acquisition, BBL would be able to direct-market more of its existing and upcoming biosimilars. To maintain customer service and facilitate a smooth transition to BBL, Viatris is expected to provide commercial and other transition services with this acquisition for an anticipated two-year term. ViatriInc.nc is a US-based pharmaceutical and healthcare corporation that has co-developed a biosimilar of pegfilgrastim.

Regional Outlook For The Global Pegfilgrastim Biosimilars Market

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

What Defines the Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Pegfilgrastim Biosimilars Industry?

The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Pegfilgrastim Biosimilars Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $1.8 billion
Revenue Forecast In 2034 $3.44 billion
Growth Rate CAGR of 17.5% from 2024 to 2033
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies Subsegments: 1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia
2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Reddy's Laboratories, Shanghai Henlius Biotech, Alvotech, EirGenix, Bharat Biotech, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Pegfilgrastim Biosimilars Market Characteristics

    3. Pegfilgrastim Biosimilars Market Trends And Strategies

    4. Pegfilgrastim Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

    5. Global Pegfilgrastim Biosimilars Growth Analysis And Strategic Analysis Framework

    5.1. Global Pegfilgrastim Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Pegfilgrastim Biosimilars Market Growth Rate Analysis

    5.4. Global Pegfilgrastim Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Pegfilgrastim Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Pegfilgrastim Biosimilars Total Addressable Market (TAM)

    6. Pegfilgrastim Biosimilars Market Segmentation

    6.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Chemotherapy Treatment

    Transplantation

    Other Applications

    6.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Mail-Order Pharmacies

    6.3. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Chemotherapy Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Supportive Care for Cancer Patients

    Reduction of Chemotherapy-Induced Neutropenia

    6.4. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hematopoietic Stem Cell Transplantation

    Peripheral Blood Stem Cell Transplantation

    6.5. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Other Applications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Treatment of Chronic Neutropenia

    Treatment of Severe Congenital Neutropenia

    Other Supportive Therapies in Oncology

    7. Pegfilgrastim Biosimilars Market Regional And Country Analysis

    7.1. Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Pegfilgrastim Biosimilars Market

    8.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Pegfilgrastim Biosimilars Market

    9.1. China Pegfilgrastim Biosimilars Market Overview

    9.2. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Pegfilgrastim Biosimilars Market

    10.1. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Pegfilgrastim Biosimilars Market

    11.1. Japan Pegfilgrastim Biosimilars Market Overview

    11.2. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Pegfilgrastim Biosimilars Market

    12.1. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Pegfilgrastim Biosimilars Market

    13.1. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Pegfilgrastim Biosimilars Market

    14.1. South Korea Pegfilgrastim Biosimilars Market Overview

    14.2. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Pegfilgrastim Biosimilars Market

    15.1. Western Europe Pegfilgrastim Biosimilars Market Overview

    15.2. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Pegfilgrastim Biosimilars Market

    16.1. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Pegfilgrastim Biosimilars Market

    17.1. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Pegfilgrastim Biosimilars Market

    18.1. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Pegfilgrastim Biosimilars Market

    19.1. Italy Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Pegfilgrastim Biosimilars Market

    20.1. Spain Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Pegfilgrastim Biosimilars Market

    21.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview

    21.2. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Pegfilgrastim Biosimilars Market

    22.1. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Pegfilgrastim Biosimilars Market

    23.1. North America Pegfilgrastim Biosimilars Market Overview

    23.2. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Pegfilgrastim Biosimilars Market

    24.1. USA Pegfilgrastim Biosimilars Market Overview

    24.2. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Pegfilgrastim Biosimilars Market

    25.1. Canada Pegfilgrastim Biosimilars Market Overview

    25.2. Canada Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Pegfilgrastim Biosimilars Market

    26.1. South America Pegfilgrastim Biosimilars Market Overview

    26.2. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Pegfilgrastim Biosimilars Market

    27.1. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Pegfilgrastim Biosimilars Market

    28.1. Middle East Pegfilgrastim Biosimilars Market Overview

    28.2. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Pegfilgrastim Biosimilars Market

    29.1. Africa Pegfilgrastim Biosimilars Market Overview

    29.2. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Pegfilgrastim Biosimilars Market Competitive Landscape And Company Profiles

    30.1. Pegfilgrastim Biosimilars Market Competitive Landscape

    30.2. Pegfilgrastim Biosimilars Market Company Profiles

    30.2.1. Amgen Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Sandoz (a Novartis division) Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Biocon Overview, Products and Services, Strategy and Financial Analysis

    31. Pegfilgrastim Biosimilars Market Other Major And Innovative Companies

    31.1. Pfizer

    31.2. Celltrion Healthcare

    31.3. Coherus BioSciences

    31.4. Gedeon Richter

    31.5. Fresenius Kabi

    31.6. Hetero Labs

    31.7. Intas Pharmaceuticals

    31.8. LG Chem

    31.9. Merck KGaA

    31.10. Zydus Cadila

    31.11. Aurobindo Pharma

    31.12. Apotex Inc.

    31.13. Dr. Reddy's Laboratories

    31.14. Stada Arzneimittel AG

    31.15. Reddy's Laboratories

    32. Global Pegfilgrastim Biosimilars Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

    34. Recent Developments In The Pegfilgrastim Biosimilars Market

    35. Pegfilgrastim Biosimilars Market High Potential Countries, Segments and Strategies

    35.1 Pegfilgrastim Biosimilars Market In 2029 - Countries Offering Most New Opportunities

    35.2 Pegfilgrastim Biosimilars Market In 2029 - Segments Offering Most New Opportunities

    35.3 Pegfilgrastim Biosimilars Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Chemotherapy Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Other Applications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: China, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: India, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: UK, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: France, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: North America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: USA, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: South America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Amgen Financial Performance
  • Table 55: Mylan N.V. Financial Performance
  • Table 56: Sandoz (a Novartis division) Financial Performance
  • Table 57: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Table 58: Biocon Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Chemotherapy Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Other Applications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: China, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: India, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: UK, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: France, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: North America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: USA, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: South America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Amgen Financial Performance
  • Figure 55: Mylan N.V. Financial Performance
  • Figure 56: Sandoz (a Novartis division) Financial Performance
  • Figure 57: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Figure 58: Biocon Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Read More

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

Read More

The Microbiome Market Share, Market Size, And Growth Rate 2022

Read More

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the radiopharmaceuticals market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the pegfilgrastim biosimilars market market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the oncology drugs market research report 2022 with industry size, share, segments and market growth

Read More

Biosimilars Global Market Report 2025 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Oncology Biosimilars Global Market Report 2025 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Trastuzumab Biosimilars Global Market Report 2025 – By Product (Ogivri, Herzuma, Ontruzant, Trazimera, Other Products), By Indication (Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications), By Distribution Channel (Hospital Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Rituximab Biosimilars Global Market Report 2025 – By Route Of Administration (Subcutaneous, Intravenous, Molecular Type), By Application (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Mail Order) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Biosimilar Hormones Global Market Report 2025 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2025 – By Product (Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Filgrastim Biosimilars Market - By Application (Oncology, Chronic and Autoimmune Diseases, Blood disorders, Growth hormone deficiency), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), And By Region, Opportunities And Strategies – Global Filgrastim Biosimilars Market Forecast To 2030

View Report

Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies - Global Forecast To 2030

View Report

Frequently Asked Questions

What is the definition of the Pegfilgrastim Biosimilars market?

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells. For further insights on the Pegfilgrastim Biosimilars market, request a sample here

How will the Pegfilgrastim Biosimilars market drivers and restraints affect the market dynamics? What forces will shape the Pegfilgrastim Biosimilars industry going forward?

The Pegfilgrastim Biosimilars market major growth driver - Government Initiatives Drive Growth In Pegfilgrastim Biosimilars Market. For further insights on the Pegfilgrastim Biosimilars market, request a sample here

What is the forecast market size or the forecast market value of the Pegfilgrastim Biosimilars market?

The Pegfilgrastim Biosimilars market size has grown strongly in recent years. The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.56 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs. The pegfilgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $3.44 billion in 2029 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing prevalence of cancer, aging population, increasing number of approvals, and targets and incentives. Major trends in the forecast period include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in R&D activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on M&A growth strategies to expand the customer base and their geographic markets, and increasing focus towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings. For further insights on the Pegfilgrastim Biosimilars market, request a sample here

How is the Pegfilgrastim Biosimilars market segmented?

The pegfilgrastim biosimilars market covered in this report is segmented –
1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies Subsegments:
1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia
2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology For further insights on the Pegfilgrastim Biosimilars market, request a sample here

Which region has the largest share of the Pegfilgrastim Biosimilars market? What are the other regions covered in the report?

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the Pegfilgrastim Biosimilars market, request a sample here.

Who are the major players in the Pegfilgrastim Biosimilars market?

Major companies operating in the pegfilgrastim biosimilars market include Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Reddy's Laboratories, Shanghai Henlius Biotech, Alvotech, EirGenix, Bharat Biotech, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm . For further insights on the Pegfilgrastim Biosimilars market, request a sample here.

What are the key trends in the Pegfilgrastim Biosimilars market?

Major trends in the Pegfilgrastim Biosimilars market include Strategic Collaborations Fueling New Launches In The Pegfilgrastim Biosimilar Market. For further insights on the Pegfilgrastim Biosimilars market, request a sample here.

What are the major opportunities in the Pegfilgrastim Biosimilars market? What are the strategies for the Pegfilgrastim Biosimilars market?

For detailed insights on the major opportunities and strategies in the Pegfilgrastim Biosimilars market, request a sample here.

How does the Pegfilgrastim Biosimilars market relate to the overall economy and other similar markets?

For detailed insights on Pegfilgrastim Biosimilars's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Pegfilgrastim Biosimilars industry?

For detailed insights on the mergers and acquisitions in the Pegfilgrastim Biosimilars industry, request a sample here.

What are the key dynamics influencing the Pegfilgrastim Biosimilars market growth? SWOT analysis of the Pegfilgrastim Biosimilars market.

For detailed insights on the key dynamics influencing the Pegfilgrastim Biosimilars market growth and SWOT analysis of the Pegfilgrastim Biosimilars industry, request a sample here.